Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence suggests that incretin-based dual agonist pharmacotherapy is helpful in persons with obesity. Mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, may have efficacy in persons with overweight or obesity. METHODS: In a phase 3, double-blind, placebo-controlled trial in China, we randomly assigned, in a 1:1:1 ratio, adults 18 to 75 years of age who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 28 or had a BMI of 24 to less than 28 plus at least one weight-related coexisting condition to receive 4 mg of mazdutide, 6 mg of mazdutide, or placebo for 48 weeks. The two primary end points were the percentage change in body weight from baseline and a weight reduction of at least 5% at week 32, as assessed in a treatment-policy estimand analysis (which assessed effects regardless of early discontinuation of mazdutide or placebo and the initiation of new antiobesity therapies). RESULTS: Among 610 participants, the mean body weight was 87.2 kg and the mean BMI was 31.1 at baseline. At week 32, the mean percentage change in body weight from baseline was -10.09% (95% confidence interval [CI], -11.15 to -9.04) in the 4-mg mazdutide group, -12.55% (95% CI, -13.64 to -11.45) in the 6-mg mazdutide group, and 0.45% (95% CI, -0.61 to 1.52) in the placebo group, and 73.9%, 82.0%, and 10.5% of the participants, respectively, had a weight reduction of at least 5% (P<0.001 for all comparisons with placebo). At week 48, the mean percentage change in body weight from baseline was -11.00% (95% CI, -12.27 to -9.73) in the 4-mg mazdutide group, -14.01% (95% CI, -15.36 to -12.66) in the 6-mg mazdutide group, and 0.30% (95% CI, -0.98 to 1.58) in the placebo group, and 35.7%, 49.5%, and 2.0% of the participants, respectively, had a weight reduction of at least 15% (P<0.001 for all comparisons with placebo). Beneficial effects on all prespecified cardiometabolic measures were seen with mazdutide. The most frequently reported adverse events were gastrointestinal and mostly mild to moderate in severity. The incidence of adverse events leading to discontinuation of the trial regimen was 1.5% with the 4-mg mazdutide dose, 0.5% with the 6-mg mazdutide dose, and 1.0% with placebo. CONCLUSIONS: In Chinese adults with overweight or obesity, once-weekly mazdutide at a dose of 4 mg or 6 mg for 32 weeks led to clinically relevant reductions in body weight. (Funded by Innovent Biologics; GLORY-1 ClinicalTrials.gov number, NCT05607680.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With mazdutide treatment, 51% of participants experienced nausea and 43% experienced vomiting, but drug discontinuation rate due to adverse events was low (2%; table).126,134”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [134]
In the citing paper
“a recent phase 3 trial (GLORY) described bodyweight reductions after 48 weeks of treatment with 6 mg/week mazdutide of 14•0% (vs an increase of 0•3% with placebo).134”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [134]
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02750-2 · Cited by 2,544
Self-citationEpidemiology and determinants of obesity in China
Pan, X.-F., Wang, L., & Pan, A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00045-0 · Cited by 1,554
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Chen, K., Shen, Z., Gu, W., Lyu, Z., Qi, X., Mu, Y., Ning, Y., & for the Meinian Investigator Group (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15238 · Cited by 393
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
Clinical management and treatment of obesity in China
Zeng, Q., Li, N., Pan, X.-F., Chen, L., & Pan, A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00047-4 · Cited by 269
Self-citationLocalio, A. R., Margolis, D. J., & Berlin, J. A. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.12.001 · Cited by 259
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., Plutzky, J., Node, K., Parkhomenko, A., Rydén, L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03015-5 · Cited by 238
le Roux, C. W., Steen, O., Lucas, K. J., Startseva, E., Unseld, A., & Hennige, A. M. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00356-x · Cited by 237
Romero-Gómez, M., Lawitz, E., Shankar, R. R., Chaudhri, E., Liu, J., Lam, R. L. H., Kaufman, K. D., Engel, S. S., Bruzone, S. O., Coronel, M. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.013 · Cited by 220
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases
Hædersdal, S., Andersen, A., Knop, F. K., & Vilsbøll, T. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00817-4 · Cited by 176
Guzman, C. B., Zhang, X. M., Liu, R., Regev, A., Shankar, S., Garhyan, P., Pillai, S. G., Kazda, C., Chalasani, N., & Hardy, T. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12958 · Cited by 172
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Lorenz, M., Lawson, F., Owens, D., Raccah, D., Roy-Duval, C., Lehmann, A., Perfetti, R., & Blonde, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0490-6 · Cited by 166
Mu, Y., Bao, X., Eliaschewitz, F. G., Hansen, M. R., Kim, B. T., Koroleva, A., Ma, R. C. W., Yang, T., Zu, N., & Liu, M. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00388-1 · Cited by 133
Zhao, L., Cheng, Z., Lu, Y., Liu, M., Chen, H., Zhang, M., Wang, R., Yuan, Y., & Li, X. (2024) · JAMA · doi:10.1001/jama.2024.9217 · Cited by 132
Uridine Metabolism and Its Role in Glucose, Lipid, and Amino Acid Homeostasis
Zhang, Y., Guo, S., Xie, C., & Fang, J. Q. (2020) · BioMed Research International · doi:10.1155/2020/7091718 · Cited by 129
Self-citationJi, L., Jiang, H., Cheng, Z., Qiu, W., Liao, L., Zhang, Y., Li, X., Pang, S., Zhang, L., Chen, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44067-4 · Cited by 118
Self-citationThe past, present, and future physiology and pharmacology of glucagon
Capozzi, M. E., D’Alessio, D. A., & Campbell, J. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.10.001 · Cited by 109
Alba, M., Yee, J., Frustaci, M. E., Samtani, M. N., & Fleck, P. (2021) · Clinical Obesity · doi:10.1111/cob.12432 · Cited by 100
Zhang, B., Cheng, Z., Chen, J., Zhang, X., Liu, D., Jiang, H., Ma, G., Wang, X., Gan, S., Sun, J., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1287 · Cited by 91
Self-citationJi, L., Gao, L., Jiang, H., Yang, J., Yu, L., Wen, J., Cai, C., Deng, H., Feng, L., Song, B., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101691 · Cited by 83
Self-citationJi, L., Jiang, H., An, P., Deng, H., Liu, M., Li, L., Feng, L., Song, B., Han-Zhang, H., Ma, Q., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101088 · Cited by 63
Self-citationTonneijck, L., Muskiet, M. H. A., Smits, M. M., Bjornstad, P., Kramer, M. H. H., Diamant, M., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13223 · Cited by 47
Winther, J. B., & Holst, J. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15693 · Cited by 47
Najafi, S., Bahrami, M., Butler, A. E., & Sahebkar, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15344 · Cited by 39
Chen, K., Chen, L., Shan, Z., Wang, G., Qu, S., Qin, G., Yu, X., Xin, W., Hsieh, T., & Mu, Y. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15360 · Cited by 35
Self-citationThe role of incretin receptor agonists in the treatment of obesity
Forst, T. M., Block, C. E. M. D., Prato, S. D., Armani, S., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15796 · Cited by 22
1866-LB: A Phase 2 Study of Mazdutide 9 mg in Chinese Adults with BMI of 30 kg/m2 or more
JIANG, H., Ji, L., ZHANG, Y., Cheng, Z., PANG, S., LI, X., QIU, W., MA, Q., LIU, Z., WANG, Y., et al. (2024) · Diabetes · doi:10.2337/db24-1866-lb · Cited by 6
Self-citationLiu, C., Xu, H., Yuan, F., Chen, H., Sheng, L., Chen, W., Xie, H., Xu, H., & Li, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1326865 · Cited by 4
Cited by
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 35
“The innovation underlying dual and even triple receptor agonists lies in their single-molecule architecture, which represents a significant advancement in peptide bioengineering.”
Self-citationMuzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Survodutide Once Weekly for the Treatment of Adults with Obesity
le Roux, C. W., Wharton, S., Startseva, E., Kloer, I. M., Hussain, S. A., Unseld, A., Bozkurt, B., Ard, J. D., Bays, H. E., Bogdański, P., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2600751 · Cited by 33
Self-citationObesity in China: current progress and future prospects
Pan, X., Fang, Z.-Z., Zhang, L., & Pan, A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00357-2 · Cited by 24
Metadata
- Authors
- Ji, L., Jiang, H., Bi, Y., Li, H., Tian, J., Liu, D., Zhao, Y., Qiu, W., Huang, C., Chen, L., Zhong, S., Han, J., Zhang, Y., Lian, Q., Yang, P., Lv, L., Gu, J., Liu, Z., Deng, H., Wang, Y., Li, L., Pei, L., & Qian, L.
- Affiliations
- Peking University People's Hospital (CN)
- Henan University of Science and Technology (CN)
- Nanjing Drum Tower Hospital (CN)
- Central Hospital of Zibo (CN)
- Department of Endocrinology, Luoyang Third People’s Hospital, Luoyang, China
- Nanyang Medical College (CN)
- Shenyang Fifth People Hospital (CN)
- Huzhou Central Hospital (CN)
- Department of Endocrinology, People’s Hospital of Xuancheng, Xuancheng, China
- Suzhou Municipal Hospital (CN)
- First People's Hospital of Kunshan (CN)
- China National Petroleum Corporation (China) (CN)
- Jiangxi Pingxiang People's Hospital (CN)
- Yan'an University (CN)
- Jilin University (CN)
- Lishui Central Hospital (CN)
- Innovent Biologics (China) (CN)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-12
- Volume
- 392
- Issue
- 22
- Pages
- 2215-2225
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4410717436
- Cited by
- 125
- References
- 32
- Citations by year
- 2026: 86 · 2025: 39
- FWCI
- 70.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Innovent Biologics
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- obesity, overweight, weight loss, GLP-1 receptor agonists, glucagon receptor agonist, weekly dosing, body mass index, weight-related comorbidities, treatment policy estimand, Chinese adults, dose comparison, early discontinuation
- MeSH terms
- East Asian People, Glucagon-Like Peptide-1 Receptor Agonists, Adolescent, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Obesity, Peptides, Weight Loss, Body Mass Index, Treatment Outcome, Receptors, Glucagon, Anti-Obesity Agents, Overweight, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.